The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

In 2022, pharmaceutical giant Pfizer (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Maybe your mom reassured you when you were younger that the cough syrup would taste "just like candy" -- usually cherry, but ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

Charlotte Allerton, Pfizer's head of medicine design, said: "The XtalPi collaboration is an opportunity to enhance our computational modelling capabilities. "We are looking forward to potentially ...

Pfizer targets $4 billion in operational savings ... molecular profiles (a trend increasingly favored in precision medicine). In short, the pipeline diversity here enables near-term commercial ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...